Last Updated : May 3, 2024
The latest CADTH Reimbursement Review reports are posted to this page. CADTH reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class. The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada's federal, provincial, and territorial governments, with the exception of Quebec. Implementation advice and funding algorithms are provided where applicable.
| Brand Name Sort ascending | Generic Name | Therapeutic Area | Recommendation Type | Project Status | Date Submission Received | Date Recommendation Issued |
|---|---|---|---|---|---|---|
| Hemangiol | Propranolol | Infantile hemangioma | Withdrawn | |||
| Hemangiol | Propranolol oral solution | Infantile hemangioma | Reimburse with clinical criteria and/or conditions | Complete | ||
| Harvoni | Ledipasvir / Sofosbuvir | Hepatitis C, chronic | List with criteria/condition | Complete | ||
| Harvoni | ledipasvir, sofosbuvir | Hepatitis C, chronic | Reimburse with clinical criteria and/or conditions | Complete | ||
| Halaven | Eribulin Mesylate | Metastatic Breast Cancer | Reimburse with clinical criteria and/or conditions | Complete | ||
| Gynazole.1 | Butoconazole nitrate | Vaginal infection | Do not list | Complete | ||
| Grastofil | Filgrastim | Neutropenia | List with clinical criteria and/or conditions | Complete | ||
| Grastek | Phleum pratense | Allergic rhinitis | Do not list | Complete | ||
| Glatect | Glatiramer acetate | Relapsing Remitting Multiple Sclerosis (RRMS) | Reimburse with clinical criteria and/or conditions | Complete | ||
| Givlaari | givosiran | Acute hepatic porphyria (AHP) in adults | Reimburse with clinical criteria and/or conditions | Complete |
Last Updated : May 3, 2024